As part of our routine diagnostic work-up, we have detected MUTYH germline heterozygous variants in a number of patients affected by breast/ovarian cancer or endometrial cancer who underwent a targeted gene panel analysis, as requested by the clinical geneticist. Here, MUTYH is linked to ovarian cancer.